PL2027140T3 - Przemysłowy sposób syntezy 17alfa-acetoksy-11beta-[4-(N,N-dimetyloamino)fenylo]-19-norpregna-4,9-dieno-3,20-dionu i nowe związki pośrednie sposobu - Google Patents

Przemysłowy sposób syntezy 17alfa-acetoksy-11beta-[4-(N,N-dimetyloamino)fenylo]-19-norpregna-4,9-dieno-3,20-dionu i nowe związki pośrednie sposobu

Info

Publication number
PL2027140T3
PL2027140T3 PL07733862T PL07733862T PL2027140T3 PL 2027140 T3 PL2027140 T3 PL 2027140T3 PL 07733862 T PL07733862 T PL 07733862T PL 07733862 T PL07733862 T PL 07733862T PL 2027140 T3 PL2027140 T3 PL 2027140T3
Authority
PL
Poland
Prior art keywords
norpregna
acetoxy
dione
diene
beta
Prior art date
Application number
PL07733862T
Other languages
English (en)
Inventor
Lajosné DANCSI
György Visky
Zoltán Tuba
János Csörgei
Csaba Molnár
Endréné Magyari
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PL2027140T3 publication Critical patent/PL2027140T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
PL07733862T 2006-06-14 2007-05-18 Przemysłowy sposób syntezy 17alfa-acetoksy-11beta-[4-(N,N-dimetyloamino)fenylo]-19-norpregna-4,9-dieno-3,20-dionu i nowe związki pośrednie sposobu PL2027140T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0600491A HU227112B1 (hu) 2006-06-14 2006-06-14 Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz
PCT/HU2007/000045 WO2007144674A1 (en) 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS
EP07733862A EP2027140B1 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17 alpha -acetoxy-11 beta -[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process

Publications (1)

Publication Number Publication Date
PL2027140T3 true PL2027140T3 (pl) 2013-09-30

Family

ID=89986843

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07733862T PL2027140T3 (pl) 2006-06-14 2007-05-18 Przemysłowy sposób syntezy 17alfa-acetoksy-11beta-[4-(N,N-dimetyloamino)fenylo]-19-norpregna-4,9-dieno-3,20-dionu i nowe związki pośrednie sposobu

Country Status (22)

Country Link
US (1) US8110691B2 (pl)
EP (1) EP2027140B1 (pl)
JP (1) JP5274453B2 (pl)
CN (1) CN101466723B (pl)
AR (1) AR061052A1 (pl)
AU (1) AU2007258955B2 (pl)
BR (1) BRPI0713157A2 (pl)
CA (1) CA2653552C (pl)
DK (1) DK2027140T3 (pl)
EA (1) EA015302B1 (pl)
ES (1) ES2409841T3 (pl)
HU (1) HU227112B1 (pl)
IL (1) IL195253A (pl)
MX (1) MX2008015972A (pl)
NO (1) NO341620B1 (pl)
PL (1) PL2027140T3 (pl)
PT (1) PT2027140E (pl)
RS (1) RS52758B (pl)
SI (1) SI2027140T1 (pl)
UA (1) UA94269C2 (pl)
WO (1) WO2007144674A1 (pl)
ZA (1) ZA200809799B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241722B (zh) * 2010-05-12 2015-11-25 杭州容立医药科技有限公司 一种合成孕酮受体调节剂优力司特的纯化方法
CN102372760A (zh) * 2010-08-12 2012-03-14 杭州容立医药科技有限公司 一种合成孕酮受体调节剂优力司特的合成方法
CN102477060B (zh) * 2010-11-22 2014-08-13 华润紫竹药业有限公司 甾体化合物及其制备方法和用途
CN102516345B (zh) 2011-11-01 2014-11-26 上海优拓医药科技有限公司 醋酸乌利司他及其关键中间体的制备方法
CN102295674B (zh) * 2011-07-14 2013-04-10 四川大学 获得高纯度17α-乙酰氧基-11β-（4-N,N-二甲氨基苯基）-19-去甲孕甾-4,9-二烯-3,20-二酮的方法
CN102344478B (zh) * 2011-07-22 2013-08-07 上海希迈医药科技有限公司 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法
CN102321141B (zh) * 2011-07-22 2013-05-15 上海希迈医药科技有限公司 一种17α-乙酰氧基-11β-（4-N,N-二甲氨基苯基）-19-去甲孕甾-4，9-二烯-3,20-二酮的无定形物及其制备方法
CN103193850A (zh) * 2012-01-04 2013-07-10 北京紫竹药业有限公司 甾体化合物的新晶型及其制备方法
CN106046099B (zh) * 2012-01-19 2018-03-16 华润紫竹药业有限公司 甾体化合物及其制备方法和用途
CN104628806A (zh) * 2012-01-19 2015-05-20 华润紫竹药业有限公司 甾体化合物及其制备方法和用途
CN102675395B (zh) * 2012-04-17 2014-04-30 常州市第四制药厂有限公司 醋酸乌利司他的多晶型及其制备方法
CN103755765B (zh) * 2012-04-17 2018-01-02 常州市第四制药厂有限公司 醋酸乌利司他的多晶型及其制备方法
CN102702296B (zh) * 2012-06-19 2014-09-03 山东诚创医药技术开发有限公司 环-3,20-双(1,2-亚乙基缩醛)-17α-羟基-17β-乙酰基-雌甾-5(10),9(11)-二烯-3-酮的制备方法
WO2014050105A1 (en) 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
US9643993B2 (en) 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014050107A1 (en) 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
CN102875629B (zh) * 2012-10-10 2014-11-19 苏州康润医药有限公司 醋酸乌利司他的合成方法
WO2014060888A1 (en) * 2012-10-18 2014-04-24 Lupin Limited Novel process and intermediate for preparation of ulipristal
CN102942612A (zh) * 2012-10-30 2013-02-27 四川大学 一种合成醋酸乌利司他的新方法
CN103804456B (zh) * 2012-11-15 2017-08-04 上海创诺医药集团有限公司 醋酸乌利司他中间体及其制备方法
CN103145787B (zh) * 2012-12-25 2017-02-22 常州市亚邦医药研究所有限公司 制备醋酸优力司特关键中间体的新方法
CN103087140A (zh) * 2013-03-04 2013-05-08 四川尚锐生物医药有限公司 一种醋酸优力司特多晶型的制备方法
CN103145788B (zh) * 2013-03-25 2015-08-19 浙江仙琚制药股份有限公司 醋酸优力司特关键中间体的制备方法
HU230319B1 (hu) * 2013-10-01 2016-01-28 Richter Gedeon Nyrt. Ipari eljárás szteroid hatóanyagok előállítására
CN103755763A (zh) * 2013-12-30 2014-04-30 烟台东诚生化股份有限公司 17α-乙酰氧基-11β-[4-(N,N-二甲基氨基)-苯基]-19-去甲孕甾-4,9-二烯-3,20-二酮的制备方法
CN104530169B (zh) * 2014-12-12 2017-09-12 成都化润药业有限公司 一种醋酸乌利司他及其中间体的制备方法
CN106986908B (zh) * 2017-03-23 2019-05-10 湖南玉新药业有限公司 倍他米松的制备方法
CN106986911B (zh) * 2017-03-23 2019-05-10 湖南玉新药业有限公司 地塞米松关键中间体联烯亚砜物的制备方法
CN108558982A (zh) * 2018-05-21 2018-09-21 郑州泰丰制药有限公司 一种新型醋酸乌利司他以及其生产制造方法
CN109053846B (zh) * 2018-08-14 2020-01-07 台州仙琚药业有限公司 制备醋酸优力司特双缩酮的方法
CN111349137A (zh) * 2018-12-21 2020-06-30 北京启慧生物医药有限公司 一种绿色合成醋酸乌利司他中间体及醋酸乌利司他的方法
CN110256519B (zh) * 2019-05-23 2021-06-08 江苏联环药业股份有限公司 一锅法制备醋酸乌利司他的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6768014B2 (en) * 1999-12-29 2004-07-27 The United States Of America As Represented By The Department Of Health And Human Services PROCESS FOR PREPARING 17α-ACETOXY-11β-[4-N,N(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS , AND PROCESSES FOR PREPARING SUCH INTERMEDIATES
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
JP2006519255A (ja) * 2003-02-28 2006-08-24 アメリカ合衆国 １７α−アセトキシ−１１β−（４−Ｎ，Ｎ−ジメチルアミノフェニル）−１９−ノルプレグナ−４，９−ジエン−３，２０−ジオンの製造方法、その中間体及びそのような中間体の製造方法
FR2854403B1 (fr) * 2003-04-29 2008-07-11 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de composes 19-nor-steroides 17-halogenes
HUP0301332A3 (en) * 2003-05-14 2006-04-28 Richter Gedeon Vegyeszet New mono-and bismethylene steroid derivatives and process for their synthesis and pharmaceutical compositions containing them
ITMI20042001A1 (it) * 2004-10-21 2005-01-21 Ind Chimica Srl Processo per la preparazione di 21-idrossi steroidi con controllo della distribuzione epimerica nella posizione c-21

Also Published As

Publication number Publication date
NO341620B1 (no) 2017-12-11
US8110691B2 (en) 2012-02-07
SI2027140T1 (sl) 2013-07-31
EP2027140B1 (en) 2013-03-13
JP2009539964A (ja) 2009-11-19
JP5274453B2 (ja) 2013-08-28
UA94269C2 (en) 2011-04-26
AU2007258955A1 (en) 2007-12-21
NO20090196L (no) 2009-03-10
HU0600491D0 (en) 2006-08-28
RS52758B (en) 2013-08-30
ZA200809799B (en) 2009-11-25
CN101466723B (zh) 2011-11-02
CA2653552A1 (en) 2007-12-21
ES2409841T3 (es) 2013-06-28
EP2027140A1 (en) 2009-02-25
EA015302B1 (ru) 2011-06-30
IL195253A (en) 2011-11-30
HU227112B1 (hu) 2010-07-28
EA200900015A1 (ru) 2009-04-28
US20090187032A1 (en) 2009-07-23
CA2653552C (en) 2013-04-23
MX2008015972A (es) 2009-01-12
DK2027140T3 (da) 2013-06-03
HUP0600491A2 (en) 2008-02-28
WO2007144674A1 (en) 2007-12-21
AR061052A1 (es) 2008-07-30
BRPI0713157A2 (pt) 2012-04-03
PT2027140E (pt) 2013-06-04
CN101466723A (zh) 2009-06-24
AU2007258955B2 (en) 2012-09-20
IL195253A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
PL2027140T3 (pl) Przemysłowy sposób syntezy 17alfa-acetoksy-11beta-[4-(N,N-dimetyloamino)fenylo]-19-norpregna-4,9-dieno-3,20-dionu i nowe związki pośrednie sposobu
HK1081945A1 (en) Process for the synthesis of 4,5-dimethoxy-1-(methylaminomethyl)-benzocy clobutane, and the use thereof
ZA200907030B (en) Industrial method for the synthesis of 17-acetoxy-11²-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
IL184694A0 (en) New polymorphous forms of rifazimin, processes for their production and use thereof in the medicinal
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
EP2070935A4 (en) NOVEL COMPOUND, COMPOSITION COMPRISING SAME, AND PROCESS FOR PRODUCING POLYMERIZABLE AMIDE
EP2189486A4 (en) MELT-LOW VISCOSITY POLYGLYCOLIC ACID, PROCESS FOR PRODUCTION THEREOF, AND USE OF MELT-LOW VISCOSITY POLYGLYCOLIC ACID
ZA201105102B (en) Process for the synthesis of l-fucosyl di-or oligosaccharides and novel 2,3,4 tribenzyl-fucosyl derivatives intermediates thereof
EP1916241A4 (en) CRYSTAL OF A PHENYLALANINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
IL234893A (en) A process for making derivatives of piperazine and diazepanyl benzamide
IL200873A0 (en) Novel benzamide derivatives and process for the preparation thereof
PL1977021T3 (pl) Przystosowana do dużych obciążeń kompozycja materiałowa zawierająca Sn; sposób wytwarzania przystosowanej do dużych obciążeń powłoki i jej zastosowanie
EP1992613A4 (en) PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE PRODUCTION METHOD
PL1937626T3 (pl) Sposób i związki do otrzymywania salmeterolu
PL1783105T3 (pl) Kompozycja zaprawowa, sposób jej wytwarzania i jej zastosowanie
ZA201000394B (en) Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
IL197876A0 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
HK1119953A1 (en) Process for the stereoselective preparation of (-)-halofenate and intermediates thereof
EP2049580B8 (de) Selbstdispergierbare silikoncopolymerisate und verfahren zu deren herstellung und deren verwendung
PL2164817T3 (pl) Nieformowany materiał ogniotrwały, sposób wytwarzania nieformowanego materiału ogniotrwałego o konsystencji wilgotnej ziemi oraz zastosowanie nieformowanego materiału ogniotrwałego
AP2376A (en) A novel process for the manufacture of 5-nonyl salicylaldoxime.
EP2011781A4 (en) METHOD FOR SYNTHESIZING AN INDENE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS OF SAID DERIVATIVE
PL2044269T3 (pl) Materiał budowlany jak również sposób jego wytwarzania i zastosowanie materiału budowlanego
WO2008110941A3 (en) New process of synthesis of a squalamine and/or trodusquemine precursor